PDGF Receptor Activation Antibody Kit

PDGF Receptor Activation Antibody Sampler Kit

Cat. Num. AAA2549981

• Applications: Western Blot
• Synonyms: PDGF Receptor Activation; PDGF Receptor Activation Antibody Sampler Kit; PDGF Receptor Activation antibody kit

• Applicable Applications for PDGF Receptor Activation antibody kit: Western Blot (WB)

Western Blot (WB)

(Western Blot analysis of Hela, KB cells using PDGFR-beta Polyclonal Antibody at dilution of 1:1000.)

Western Blot (WB)

(Western Blot analysis of various cells using SH-PTP2 Polyclonal Antibody at dilution of 1:2000.)

Western Blot (WB)

(Western Blot analysis of HuvEc cells with Phospho-SH-PTP2 (Tyr542) Polyclonal Antibody at dilution of 1:1000)

Western Blot (WB)

(Western Blot analysis of MCF7 cells with Phospho-Akt (Ser473) Polyclonal Antibody at dilution of 1:1000)

Western Blot (WB)

(Western Blot analysis of 293T cells using Pan-Akt Polyclonal Antibody at dilution of 1:1000.)

Western Blot (WB)

(Western Blot analysis of HepG2, Hela cells using ERK 1/2 Polyclonal Antibody at dilution of 1:1000.)

Western Blot (WB)

(Western Blot analysis of Hela, 293 cells with Phospho-ERK 1/2 (Thr202/Tyr204) Polyclonal Antibody)

Related Product Information for PDGF Receptor Activation antibody kit

Background: Platelet derived growth factor (PDGF) family proteins form dimers (PDGF AA, PDGF AB, PDGF BB, PDGF CC, and PDGF DD) that bind receptor tyrosine kinases PDGF receptor alpha (PDGFRalpha) and PDGF receptor beta (PDGFRbeta) in a specific pattern. PDGFRbeta homodimers bind PDGF BB and DD homodimers and the PDGF AB heterodimer. Heteromeric receptor PDGF alpha/beta binds PDGF B, C, and D homodimers and the PDGF AB heterodimer. Ligand binding induces PDGF receptor dimerization and autophosphorylation, followed by binding and activation of cytoplasmic SH2 domain-containing signal transduction molecules, such as GRB2, Src, GAP, PI3 kinase, PLCgamma, and NCK. Activated PDGF receptors initiate signaling pathways that control cell growth, actin reorganization, migration, and differentiation. PDGFRbeta kinase-insert region residue Tyr751 forms the PI3 kinase docking site, and phosphorylation of PDGFRbeta at this site inhibits the association between the SH2 domain of the PI3 kinase p85 subunit and PDGFRbeta. SHP-2 (PTPN11) is a nonreceptor protein tyrosine phosphatase that participates in signaling pathways that control cell growth, differentiation, migration, and death. Activation of SHP-2 and its association with Gab1 is critical for sustained Erk activation downstream of growth factor receptors and cytokines. Phosphorylation of SHP-2 at Tyr542 and Tyr580 in response to growth factor receptor activation is thought to relieve basal inhibition and stimulate SHP-2 tyrosine phosphatase activity. Insulin and various growth/survival factors activate Akt, a kinase that acts in a wortmannin- sensitive pathway involving PI3 kinase to help control survival and apoptosis. Akt is activated by phospholipid binding and activation loop phosphorylation at Thr308 by PDK1 and by phosphorylation within the carboxy terminus at Ser473. The p44/42 MAPK (Erk1/2) signaling pathway is activated in response to extracellular stimuli including mitogens, growth factors, and cytokines. Research suggests that this pathway is an important target in cancer identification and treatment. External stimuli lead to activation of a kinase cascade that results in the activation of p44 and p42 by a MAP kinase. MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Clinical studies describe PDGF expression in a number of different solid tumors, from glioblastomas to prostate carcinomas. The biological role of PDGF signaling in these tumors varies from autocrine stimulation of cancer cell growth to more subtle paracrine interactions involving adjacent stroma and even angiogenesis. Targeting PDGF signaling may be an effective way for tumor treatment.